BOT announced positive results from its BTX 1801 Phase 2a nasal decolonisation proof of concept study.  We upgrade to SPEC BUY (prior HOLD) as these results highlight CBD’s potential as a new treatment for resistant bacteria.

To access the full report please log in under the Client Area at the bottom of this page.

Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.

If you would like to access our research please contact us to create an account.